CVS Health Corporation $CVS Shares Acquired by Prevail Innovative Wealth Advisors LLC

Prevail Innovative Wealth Advisors LLC increased its stake in shares of CVS Health Corporation (NYSE:CVS) by 94.4% during the third quarter, Holdings Channel.com reports. The institutional investor owned 23,611 shares of the pharmacy operator’s stock after buying an additional 11,465 shares during the quarter. Prevail Innovative Wealth Advisors LLC’s holdings in CVS Health were worth $1,780,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Harbor Capital Advisors Inc. grew its stake in CVS Health by 72.1% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator’s stock valued at $26,000 after purchasing an additional 142 shares during the last quarter. Corundum Trust Company INC purchased a new position in shares of CVS Health in the third quarter worth about $29,000. Front Row Advisors LLC lifted its holdings in shares of CVS Health by 436.5% during the second quarter. Front Row Advisors LLC now owns 456 shares of the pharmacy operator’s stock worth $31,000 after purchasing an additional 371 shares during the period. Twin Peaks Wealth Advisors LLC purchased a new stake in CVS Health in the second quarter valued at approximately $36,000. Finally, SOA Wealth Advisors LLC. increased its holdings in CVS Health by 36.9% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator’s stock worth $37,000 after buying an additional 131 shares during the period. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Stock Down 1.0%

CVS opened at $77.91 on Friday. The company has a fifty day moving average of $78.49 and a two-hundred day moving average of $77.60. The stock has a market capitalization of $99.12 billion, a price-to-earnings ratio of 56.46, a PEG ratio of 0.81 and a beta of 0.49. CVS Health Corporation has a fifty-two week low of $58.35 and a fifty-two week high of $85.15. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.63 and a current ratio of 0.84.

CVS Health (NYSE:CVS) last posted its earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.09. The firm had revenue of $105.69 billion for the quarter, compared to analysts’ expectations of $103.67 billion. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The company’s quarterly revenue was up 8.2% on a year-over-year basis. During the same period last year, the firm earned $1.19 EPS. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. On average, research analysts expect that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Thursday, January 22nd were given a dividend of $0.665 per share. The ex-dividend date was Thursday, January 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.4%. CVS Health’s dividend payout ratio (DPR) is 192.75%.

Wall Street Analyst Weigh In

Several analysts have commented on CVS shares. Weiss Ratings restated a “hold (c-)” rating on shares of CVS Health in a research note on Monday, December 29th. Leerink Partners restated an “outperform” rating and set a $98.00 target price on shares of CVS Health in a research report on Thursday. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $91.00 price target on shares of CVS Health in a research report on Tuesday, January 6th. Cantor Fitzgerald restated an “overweight” rating on shares of CVS Health in a research note on Wednesday, December 10th. Finally, Bank of America dropped their target price on CVS Health from $100.00 to $95.00 and set a “buy” rating on the stock in a report on Tuesday, January 27th. Nineteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $94.91.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS launched Health100, a new AI-native health‑tech subsidiary and consumer engagement platform built with Google Cloud. Management says the platform will unify data across payers, providers and pharmacies to drive personalized engagement and better outcomes — a potential long‑term revenue and margin lever if adoption scales. CVS taps Google Cloud to roll out AI-powered health platform
• Positive Sentiment: Broad media and trade coverage highlights the Google Cloud tie‑up and Health100 rollout, increasing visibility for CVS as a tech-enabled healthcare integrator — this can support multiple revenue streams (retail, PBM, value-based care) over time. CVS Health And Google Launch AI Business To ‘Personalize Healthcare’
• Positive Sentiment: Analyst and long‑term bulls point to margin recovery and FY2026 guidance (CVS set EPS guidance ~5.94–6.14) plus a recent quarterly beat — supporting the thesis that Medicare Advantage margin improvement and Health100 monetization could drive sizable upside over 12–24 months. CVS Health: Stop Catastrophizing, Start Believing – Here’s Why
• Neutral Sentiment: Market commentary questions whether recent gains already price in recovery — some pieces analyze valuation and one‑year returns, useful for timing but not a direct catalyst. Is CVS Health (CVS) Still Attractive After A 27% One Year Share Price Gain
• Negative Sentiment: Regulatory risk in Tennessee: a proposed bill would bar companies from owning both retail pharmacies and PBMs, and CVS warned it could close all 134 locations in the state if the law passes — an example of state‑level regulatory risks that could hit revenue, footprint and investor sentiment. CVS warns bill would force shutdown of 134 pharmacies in this state
• Negative Sentiment: Wolfe Research trimmed its price target on CVS, a modest negative for near‑term sentiment even though the firm remains focused on longer‑term fundamentals. Wolfe Research Cuts CVS Health (NYSE:CVS) Price Target to $97.00

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.